[1. Lichtman LA, Liesveld JL. CML and related disorders, in Williams Hematology, McGraw Hill 8th edition, 1085-1124.]Search in Google Scholar
[2. Petrov L, Cucuianu A, Bojan A, Urian L. Leucemia granulocitara cronica. In “Hematologie Clinica”. Casa Cartii de Stiinta, Cluj-Napoca, 2009: 45-63]Search in Google Scholar
[3. Apperley JF. Mechanism of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol, 2007, 8:1018-102910.1016/S1470-2045(07)70342-X]Search in Google Scholar
[4. Quintas-Guardama A, Kantarjian H, Cortes J. Mechanism of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control, 2009, 16: 122-131.10.1177/10732748090160020419337198]Search in Google Scholar
[5. Bixby D, Talpaz M. Mechanism of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology 2009, 1: 461-47610.1182/asheducation-2009.1.46120008232]Search in Google Scholar
[6. Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate- resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML. Leukemia 2006, 20: 1061-106610.1038/sj.leu.240423616642048]Search in Google Scholar
[7. Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M et al. Clinical outcome of 27 imatinib mesylate resistant chronic myelogenous leukemia patients harboring T315I BCR-ABL mutation. The Hematology Journal 2007, 92: 1238-124110.3324/haematol.1136917768119]Search in Google Scholar
[8. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood, 2009, 114: 5271-5278.10.1182/blood-2009-04-219410491693919843886]Search in Google Scholar
[9. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol, 2009, 27: 4204-421010.1200/JCO.2009.21.8230497923019652056]Search in Google Scholar
[10. Muller Mc, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic phase chronic myeloid leukemia, analysis of responses according to preexisting BCR-ABL mutations. Blood, 2009, 114:4944-495310.1182/blood-2009-04-214221491694019779040]Search in Google Scholar
[11. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood, 2007, 110: 2828-3710.1182/blood-2007-04-03894317626839]Search in Google Scholar
[12. Roche-Lestienne C, Soenen-Cornu V, Grardel- Duflos N, Laï JL, Philippe N, Facon T et all. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 2002, 100:1014-101810.1182/blood.V100.3.1014]Search in Google Scholar
[13. Khorashad JS, Thelwell N, Milojkovic D, Marin D, Watson JA, Goldman JM, Apperley JF et al. A new rapid and sensitive assay for detecting the chronic myeloid leukemia T315I BCR-ABL kinase domain mutation in chronic myeloid leukemia. J Clin Pathol. 2008, 61, 863-86510.1136/jcp.2008.05680418587017]Search in Google Scholar
[14. Y M Dennis Lo. The amplification refractory mutation system. Methods in Molecular Medicine, 1998, 16: 61-69]Search in Google Scholar
[15. Dima D, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation in chronic myeloid leukemia by amplification refractory mutation system PCR. Rev Rom de Med de Lab, 2008, 13:17-20]Search in Google Scholar
[16. Marin D, Ibrahim Amr R, Goldman JM. European treatment and outcome study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol, 2011, 29: 3944-394510.1200/JCO.2011.37.696221900102]Search in Google Scholar
[17. Cortes J, Lipton JH, Rea D, Diqumarti R, Chuah C, Nanda N et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with CML with T315I mutation. Blood, 2012, 120:2573-258010.1182/blood-2012-03-415307491658322896000]Search in Google Scholar
[18. Wei G, Rafiyath S and Liu D. First line treatment of chronic myeloid leukemia: dasatinib, nilotinib or imatinib. J Hematol Oncol, 2010, 3: 47-5210.1186/1756-8722-3-47300036921108851]Search in Google Scholar
[19. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome- positive leukemias. N Eng J Med, 2012, 367:2075-8810.1056/NEJMoa1205127377738323190221]Search in Google Scholar
[20. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011, 118:1208-1215 10.1182/blood-2010-12-32640521562040]Search in Google Scholar